admin

  • ORBITA Trial: PCI Versus Sham Procedure in Stable Angina

    ORBITA Trial: PCI Versus Sham Procedure in Stable Angina

    The ORBITA trial was a landmark study in interventional cardiology because it tested whether percutaneous coronary intervention, or PCI, improves symptoms in patients with stable angina when compared with a placebo procedure. Unlike many earlier PCI studies, the ORBITA trial used a double-blind sham-controlled design, making it one of the most rigorous trials ever performed…

    read more

  • COURAGE Trial: Optimal Medical Therapy With or Without PCI for Stable Coronary Disease

    COURAGE Trial: Optimal Medical Therapy With or Without PCI for Stable Coronary Disease

    The COURAGE trial was one of the most important landmark cardiology trials because it challenged the routine use of percutaneous coronary intervention, or PCI, in patients with stable coronary artery disease. Before COURAGE, many patients with stable coronary blockages underwent PCI with the expectation that opening the artery would reduce future heart attacks or death.…

    read more

  • ISCHEMIA Trial: Initial Invasive vs Conservative Strategy in Stable Coronary Disease

    ISCHEMIA Trial: Initial Invasive vs Conservative Strategy in Stable Coronary Disease

    The ISCHEMIA trial was one of the most important cardiovascular trials evaluating whether an early invasive strategy improves outcomes in patients with stable coronary artery disease and moderate or severe ischemia. For decades, many clinicians assumed that finding significant ischemia on stress testing meant that patients would benefit from early cardiac catheterization and revascularization. The…

    read more

  • SCORPIO-PEP Trial: Ensitrelvir for Covid-19 Postexposure Prophylaxis in Household Contacts

    SCORPIO-PEP Trial: Ensitrelvir for Covid-19 Postexposure Prophylaxis in Household Contacts

    The SCORPIO-PEP trial evaluated ensitrelvir as postexposure prophylaxis for household contacts of Covid-19 patients and showed a significant reduction in symptomatic Covid-19 by day 10. Introduction The SCORPIO-PEP trial evaluated whether ensitrelvir, an oral antiviral agent, could prevent Covid-19 in people recently exposed to SARS-CoV-2 within their household. Household exposure remains one of the highest-risk…

    read more